logo-loader
viewVolitionRx

VolitionRX appoints high profile cancer consultant to boost funding in Texas

Over the past six years Vollmer Dahlke has raised over US$25mln in non-dilutive grants

picture of Texas flag
Volition America has set up in Texas

VolitionRx Limited’s (NYSE:VNRX) US subsidiary Volition America has appointed Dr Deborah Vollmer Dahlke as a strategic consultant to help it get funding in Texas and elsewhere in the US.

Over the past six years Vollmer Dahlke has raised over US$25mln in non-dilutive grants from the Cancer Prevention and Research Institute of Texas (CPRIT) for her clients.

She is a director of the Texas Life Science Foundation and is actively involved in helping to develop Texas's biotech funding infrastructure as well as being one of several authors of the current Texas Cancer Plan, one of CPRIT's legislative requirements.

This aims to co-ordinate, prioritize and provide an actionable framework to fight the effects of cancer in Texas.

Jason Terrell Volition America’s chief executive, said: "We are delighted to be working with Dr. Vollmer Dahlke to help identify and secure funding to further our development of blood-based cancer diagnostic tests for the US.

“The fact that Texas is one of the leading life science states was a key driver in our decision to make this the home of Volition America, Inc.” 

Shares nudged 1.19% higher in New York  to stand at $4.25.

Quick facts: VolitionRx

Price: 4.62 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $189.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

4 days, 8 hours ago

2 min read